Merck Sharp + Dohme Corp.

Biogen Ma Inc.

Sunesis Pharmaceuticals, Inc.

Rib-x Pharmaceuticals, Inc.

Biogen Idec Ma Inc.

Melinta Therapeutics, Inc.

Other

Millennium Pharmaceuticals Limited

Bioverativ Therapeutics Inc.

Millenium Pharmaceuticals, Inc.

Msd R&d (china) Co., Ltd.

Msd R&d Co., Ltd.

Deping Wang

Scott D Kuduk

Gnanasambandam Kumaravel

Jay J Farmer

Ashoke Bhattacharjee

Joseph M Salvino

Daniel M Scott

Jiacheng Zhou

Brian T Hopkins

Shili Chen

Patrick R Conlon

Min Zhong

Kevin Guckian

Junfa Fan

Alexey Alexandrovich Lugovskoy

Dong-Ming Shen

Liangqin Guo

Mark E Layton

Thomas J Greshock

Ronald M Kim

Arthur G Taveras

Yimin Qian

Zhili Xin

Bin Ma

Sha Mi

Philippe G Nantermet

Michael P Dwyer

Shawn J Stachel

Daniel Vincent Paone

Wen-Cherng Lee

XiaoXia Qian

Mark E Fraley

Volker Schellenberger

Robert T Peters

Joshua A Silverman

Melissa S Egbertson

Justin Andrew Caravella

Craig A Stump

Willem P Stemmer

Younong Yu

Jian Liu

James J Perkins

Jason M Cox

Christopher S Burgey

Haiyan Jiang

Hong Liu

Cheng Wang

Chia-wei Wang

Helen Y Chen

Helen J Mitchell

Rongliang Lou

Adegboyega K Oyelere

Joel A Goldberg

Yusheng Wu

Daniel A Erlanson

Yi C Chen

Tracy J Jenkins

Bing Guan

Noel Aaron Powell

Lei Zhang

Jennifer N Tran

Lihong Sun

Roger Hanselmann

Minna Bui

Julio Hernan Cuervo

Anthony J Roecker

Richard Berger

Joseph A Ippolito

James J Mulhearn

Walter Won

Joyce A Sutcliffe

Ting Zhang

Rajan Anand

Christopher Joseph Sinz

Shimin Xu

Gang Zhou

Zhaohui Shao

Edward Yin-Shiang Lin

Erin M Duffy

Jermaine Thomas

Zoltan F Kanyo

Timothy Raymond Chan

Hairuo Peng

Michael J Kelly, Iii

Edward C Sherer

Jianmin Fu

Nathan C Geething

Junying Zheng

Xuanjia Peng

John D Kulman

Christopher James Bungard

William D Shipe

Benjamin Spink

Tongyao Liu

Kenneth J Simon

John E Stelmach

Deyou Sha

Abbas M Walji

Mehul F Patel

Alexey V Ishchenko

Disclosed are compounds of Formula A, or a salt thereof: Wherein 'A', R, R, R, R, and Rare as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch and neuropathic pain disorders using the same.

Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels

The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases. 

3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and Rto Rare defined herein, which compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same. 

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Bruton's tyrosine kinase inhibitors

Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same. 

The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.

Factor VIII compositions and methods of making and using same

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Pyrazolyl pyrimidinone compounds as PDE2 inhibitors

The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction. 

Pyrimidinone amide compounds as PDE2 inhibitors

Disclosed are compounds of Formula A, or a salt thereof: wherein R, R, and E are defined herein, which compounds have properties for inhibiting Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.

Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels

The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction. 

6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Heterocyclic compounds useful as PDK1 inhibitors

Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.

ATX modulating agents

Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof. 

Pyrimidone carboxamide compounds as PDE2 inhibitors

Growing community of inventors

Furlong, PA, United States of America

Deping Wang